1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Effect of the thirddose of BNT162b2vaccine inquantitativeSARS-CoV-2 spike 1-2IgG antibody titersin healthcare workers María ElenaRomero-IbarguengoitiaDiego Rivera-SalinasYodira GuadalupeHernández-Ruíz2021 год

Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers
preprint

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Abstract Background Vaccination is our main strategy to control SARS-CoV-2 infection. Given a decrease in the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months following the second BNT162b2 dose, healthcare workers got a third booster dose after six months of completing the original scheme. This study aimed to analyze quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and safety of the third dose. Material and methods A prospective longitudinal cohort study included healthcare workers who received a third booster dose after six months of the complete BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the complete scheme, 1-7 days following the third dose, and 21-28 days after the boost. Results The cohort comprised 168 non-immunocompromised participants of 41(10) years old, 67% being women. The third dose was associated with increasing the quantitative antibody titers, regardless of previous SARS-CoV-2 history. In negative SARS-CoV-2 history, the median (IQR) antibody titers increased from 379 (645.4) to 2960 (2010), while in positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080). The third dose had less number of total side effects compared to the other two shots. The most common side effect after the third BNT162b2 shot was pain at the injection site (n=82, 84.5%), followed by tiredness (n=45, 46.4%), with a mild severity (n=36, 37.1%). Tiredness, myalgias, arthralgias, fever, and adenopathy were proportionally higher following the third dose than the two-dose regimen (p<0.05). Conclusion The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated with no severe side effects after the additional BNT162b2 dose.
Год издания: 2021
Авторы: María Elena Romero-Ibarguengoitia, Diego Rivera-Salinas, Yodira Guadalupe Hernández-Ruíz, Ana Gabriela Armendariz-Vázquez, Arnulfo González-Cantú, Irene Antonieta Barco-Flores, Rosalinda González-Facio, Laura Patricia Montelongo-Cruz, Gerardo Francisco Del Rio-Parra, Mauricio René Garza-Herrera, Jessica Andrea Leal-Meléndez, Miguel Ángel Sanz-Sánchez
Издательство: Cold Spring Harbor Laboratory
Источник: medRxiv (Cold Spring Harbor Laboratory)
Ключевые слова: SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Infection Control and Ventilation
Другие ссылки: medRxiv (Cold Spring Harbor Laboratory) (HTML)
journals.plos.org (PDF)
doi.org (HTML)